Implications of plasma concentrations of adiponectin in patients with coronary artery disease - PubMed (original) (raw)

doi: 10.1136/hrt.2003.011114.

K Shimada, D Fukuda, Y Shimada, S Ehara, M Hirose, T Kataoka, K Kamimori, S Shimodozono, Y Kobayashi, M Yoshiyama, K Takeuchi, J Yoshikawa

Affiliations

Implications of plasma concentrations of adiponectin in patients with coronary artery disease

Y Nakamura et al. Heart. 2004 May.

Abstract

Objective: To investigate whether concentrations of plasma adiponectin constitute a significant coronary risk factor, with particular focus on the relation between plasma concentrations of adiponectin and the development of acute coronary syndrome (ACS).

Subjects and methods: Plasma concentrations of adiponectin were measured in 123 patients with coronary artery disease (CAD) and in 17 control participants. Patients were divided into three groups according to condition type: acute myocardial infarction (AMI) group (n = 59), unstable angina pectoris (UAP) group (n = 28), and stable angina pectoris (SAP) group (n = 36).

Results: Plasma concentrations of adiponectin correlated negatively with body mass index (r = -0.18, p < 0.05), serum triglyceride (r = -0.25, p < 0.01), and fasting glucose concentrations (r = -0.21, p < 0.05), but correlated positively with age (r = 0.26, p < 0.01), high density lipoprotein cholesterol concentrations (r = 0.35, p < 0.01), and low density lipoprotein particle size (r = 0.37, p < 0.01). Plasma concentrations of adiponectin in patients with ACS, in both the AMI and UAP groups, were significantly lower than those in patients with SAP and in the control group (ACS, 6.5 (3.0) microg/ml; SAP, 11.3 (5.9) micro g/ml; control 12.8 (4.3) microg/ml; p < 0.01). Additionally, plasma concentrations of adiponectin in patients with CAD (7.9 (4.6) microg/ml, p < 0.01) were significantly lower than in the control group. There were, however, no significant differences between patients with SAP and the control group (p = 0.36). Multiple logistic regression analysis showed that smoking, fasting glucose concentration, and low log adiponectin concentration correlated independently with the development of an ACS.

Conclusions: The findings suggest that measurement of plasma concentrations of adiponectin may be of use for assessing the risk of CAD and may be related to the development of ACS.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Correlation of plasma concentrations of adiponectin with (A) body mass index, (B) low density lipoprotein (LDL) particle size, (C) age, and (D) triglyceride. Plasma concentrations of adiponectin correlated with body mass index, LDL particle size, age, and triglyceride.

Figure 2

Figure 2

Correlation of plasma concentrations of adiponectin with (A) high density lipoprotein (HDL) cholesterol, (B) total cholesterol, (C) LDL cholesterol, and (D) fasting glucose. Plasma concentrations of adiponectin correlated with HDL cholesterol and fasting glucose concentrations. Total cholesterol concentrations and LDL cholesterol concentrations did not correlate with plasma concentrations of adiponectin.

Figure 3

Figure 3

Plasma concentrations of adiponectin were significantly lower in men with coronary artery disease (CAD) than in women with CAD (p < 0.01) (see fig 4).

Figure 4

Figure 4

Graph showing plasma concentrations of adiponectin in patients with acute myocardial infarction (AMI), unstable angina pectoris (UAP), stable angina pectoris (SAP) and no coronary artery disease (CAD) (control group). Plasma concentrations of adiponectin in patients with AMI were significantly lower than those in patients with SAP and without CAD (p < 0.01). In addition, plasma concentrations of adiponectin in patients with UAP were significantly lower than those in patients with SAP and without CAD (p < 0.01).

References

    1. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999;892:146–54. - PubMed
    1. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595–9. - PubMed
    1. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473–6. - PubMed
    1. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000;32:47–50. - PubMed
    1. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057–63. - PubMed

MeSH terms

Substances

LinkOut - more resources